Best ASX 200 shares vs. best suburbs for property investment in 2023

Looking at the overall capital growth of shares vs. property in 2023, we saw a dead heat with the S&P/ASX 200 Index (ASX: XJO) and CoreLogic's national Home Value Index both rising by 8.1%.

In this article, we investigate the numbers further to reveal the top 10 ASX 200 shares for capital gains vs. the top 10 suburban property markets of Australia's capital cities and regional areas.

Let's take a look.

Top 10 suburbs for real estate investment in 2023 (capital cities)

Here are the top 10 suburbs for capital growth across Australia's capital city property markets in 2023.

Top 10 suburbs for real estate investment in 2023 (regions)

Here are the top 10 suburbs for capital growth across Australia's regional property markets in 2023.

Top 10 ASX 200 shares of 2023

Here are the top 10 ASX 200 shares for capital growth in 2023.

If you're considering investing in shares vs. property, check out our article on the opportunities of 2024.

mid-cap healthcare stocks. However, those that achieved material commercial milestones have generated positive shareholder returns in the last six months (NEU, DXB, 4DX and PME). With many companies currently trading at depressed valuations, there are stock picking opportunities for those with solid balance sheets to ride out the cyclical downturn and clear catalysts to drive momentum.The new class of GLP-1/GIP drugs continue to dominate news flow for their impact on weight loss and other health outcomes (e.g. lowering cardiovascular events). There is little doubt these drugs will form one of the biggest selling classes to date, with both Novo Nordisk and Eli Lilly unable to keep up with demand. ASX large-cap healthcare companies, including RMD and CSL were sold off as investors drew read throughs for what these drugs could mean for long term demand growth. Fortunately there were no adverse impacts on companies in our coverage and data suggests the sell off in large cap stocks has been overdone in any case